These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Euscher ED; Malpica A; Deavers MT; Silva EG Am J Surg Pathol; 2005 Aug; 29(8):1074-8. PubMed ID: 16006803 [TBL] [Abstract][Full Text] [Related]
9. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma. Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017 [TBL] [Abstract][Full Text] [Related]
10. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839 [TBL] [Abstract][Full Text] [Related]
11. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. Lin CK; Chao TK; Yu CP; Yu MH; Jin JS APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589 [TBL] [Abstract][Full Text] [Related]
12. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Al-Hussaini M; Stockman A; Foster H; McCluggage WG Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054 [TBL] [Abstract][Full Text] [Related]
13. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma. Mondal SK; Basak B; Bhattacharya S; Panda UK J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149 [TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of mesothelial and ovarian cancer cells in ascites by immunocytochemistry using Ber-EP4 and calretinin. Sato S; Okamoto S; Ito K; Konno R; Yajima A Acta Cytol; 2000; 44(3):485-8. PubMed ID: 10834020 [No Abstract] [Full Text] [Related]
15. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells. Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504 [TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416 [TBL] [Abstract][Full Text] [Related]
17. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases. Mansor S; McCluggage WG Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962 [TBL] [Abstract][Full Text] [Related]
18. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Roh MH; Kindelberger D; Crum CP Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565 [TBL] [Abstract][Full Text] [Related]
19. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features]. Guo DH; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254 [No Abstract] [Full Text] [Related]
20. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]